Drugs / Aclamycin
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05659992 | Dec 2022 → Aug 2023 | acute myeloid leukemia | Chinese PLA General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04541277 | Sep 2020 → Aug 2021 | acute myeloid leukemia | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aclamycin | “Aclamycin hydrochloride, 20 mg/d, IV, on day 1, 3, and 5 (For relapse/resistance AML, on days 1-5.).” NCT04541277 ↗ |
| Route | Intravenous | “Aclamycin hydrochloride, 20 mg/d, IV” NCT04541277 ↗ |